Prosonix appoints chief medical officer

Oxford firm hires respiratory drug development expert Dr Geoff Down

Prosonix, an emerging pharmaceutical company based in Oxford, UK, has appointed Dr Geoff Down to the newly created role of chief medical officer. Down will oversee the clinical development of Prosonix’s respiratory product pipeline, including PSX1001, PSX1002 and the new PSX2000 combination series.

Down has more than 18 years’ clinical development experience in the pharmaceutical sector, following 10 years in clinical practice.

He joins Prosonix after running his own company, providing services as a consultant pharmaceutical physician. During this period he worked in clinical safety for Pfizer r&d, in clinical development for RespiVert Ltd (a spinout from Imperial Innovations that aims to identify new treatments for COPD, cystic fibrosis and severe asthma), and since December 2010 he has been working in clinical pharmacology at GlaxoSmithKline’s r&d Respiratory and Immuno-Inflammation medicines development centre (GSK RII MDC).

Dr Down has been a principal investigator or company sponsor for more than 50 early clinical development studies, including first-in-human studies, and in excess of 30 full clinical development trials.

You may also like

Research & Development

Proposed acquisition of Aerocrine and Prosonix by Circassia Pharmaceuticals

Creating a world-class speciality pharmaceutical allergy and asthma business
Research & Development

Prosonix receives £1.3m grant from the Biomedical Catalyst

To accelerate development of Multi-component particle (MCP) based combination respiratory medicines
Research & Development

Prosonix collaboration to speed up development of respiratory medicines

Prosonix and Imperial College London to accelerate development of engineered Multi-component Particles
Drug Delivery

Prosonix develops multi-component drug particles combining two respiratory drugs

To ensure optimal co-localisation in the lung
Research & Development

Prosonix offers co-crystal development service

Aimed at the manufacturing of co-crystals for use in inhaled and oral medicines
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
Subscribe now